working on the vaccine at oxford. thank you so much for being here, professor. appreciate your time. lay out for us the promising signs you are seeing with your vaccine. >> what we've reported today in the lancet is a new data set on the phase one trial at our vaccine meaning just over a thousand people. firstly the safety data looks very reassuring in all of those individuals. no serious adverse events, nothing of significant concern. and then when we look at the immune responses they are present in everybody. we see good, neutralizing antibodies. these are the ones we are looking for that should inhibit the infection of the virus into cells. in addition we see the cellular arm, usually called t-cells, which are there in large numbers as well even after a single dose of the vaccine. so really, results at the high end of our expectations.